奥氮平与利培酮治疗青少年首发精神分裂症对照研究

A comparative study of olanzapine and risperidone in the treatment of adolescents with first-episode schizophrenia

目的比较奥氮平与利培酮治疗青少年首发精神分裂症的疗效和安全性。方法对60例青少年期首发精神分裂症患者随机分为两组,分别给予奥氮平与利培酮治疗8周。于治疗前及治疗后1、2、6、8周末进行阳性和阴性症状量表(PANSS)及副反应量表(TESS)评定。结果奥氮平与利培酮总的疗效无显著性差异,均能快速起效,PANSS总分比较治疗第1周与第2周末奥氮平组显著低于利培酮组,利培酮组锥体外系反应显著多于奥氮平组。结论奥氮平与利培酮均是治疗首发青少年精神分裂症安全有效的非典型抗精神病药物,可根据患者的不同情况分别选择。

Objective To compare the efficacy and safety of olanzapine and risperidone in the treatment of adolescents with first-episode schizophrenia. Methods A total of 60 adolescents with first-episode schizophrenia were randomly divided into olanzapine group （n = 30）and risperidone group （n = 30）for 8 weeks. Positive and Negative Symptoms Scale（PANSS） and Treatment Emergent Symptom Scale（TESS） were used to measure the efficacy and safety before treatment and the end of 1st , 2nd,4th, 6th and 8th week after treatment. Results There was no significant difference on eFficacy between two groups, and two groups took effect immediately. The scores of PANSS in olanzapine group were significantly lower than those in risperidone group on the end of 1st and 2nd week after treatment. The expyramidal symptoms （EPS）in risperidone group were significantly more than those in olanzapine group. Conclusion Olanzapine and risperidone both are safe and effective agents for treating adolescents with first-episode schizophrenia.